Fresenius SE & Co. KGaA

FRE.DE

Medical - Care Facilities · Healthcare

Exchange

Frankfurt Stock Exchange (XETRA)

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Aug 23, 2026 · filings through Mar 31, 2026

How the score breaks down

Quality

Mixed

Growth

Strong

Cash Flow

Strong

Stability

Strong

Valuation

Strong

Dividends

Strong

Track this stock — start free trial

Winston Score History

The full picture

Fresenius is a German healthcare company that runs hospitals, provides medical treatments, and sells medical products to patients and healthcare systems around the world. Its main businesses include Helios, one of Europe's largest private hospital networks, and Kabi, which makes intravenous drugs, clinical nutrition products, and medical devices used in hospitals. The company serves patients, doctors, and national health systems across Europe, Latin America, and beyond.

Fresenius earns money by charging for hospital services, selling generic injectable drugs, and supplying nutrition and infusion products to clinics and hospitals. It operates in over 40 countries and generates roughly €22 billion in annual revenue, giving it significant scale in European private healthcare. Its main competitive advantage is the combination of a large captive hospital network and an in-house drug and device supply business, which creates cost efficiencies. The key risk is ongoing pressure from government healthcare budgets in Europe, which can limit how much Fresenius can charge for its services and products.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+3.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+100.0% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

27.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

€5.1B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Fresenius SE & Co. KGaA is growing revenue at 3% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

26.4%

Modest — 26.4% gross margin

Profit after running costs

Operating Margin

10.8%

Modest — 10.8% operating margin

Return on the money invested

ROCE

7.2%

Weak — 7.2% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+4.6%

Slow sales growth (+4.6% YoY)

Profit growth

EPS YoY

+250.0%

Earnings growing fast (+250.0% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

199%

Turns 199% of profit into real cash

Spare cash per sale

FCF Margin

6.3%

Modest free cash flow (6.3%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.53

Conservative — low debt load (0.53)

Covers its interest

Interest Cover

6.87x

Adequate interest coverage (6.9x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

17.0x

no trend

Fair value — P/E 17.0

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year

P/E vs Forward

+6.6

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (17.0 → 10.4)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

2.37%

no trend

Moderate income — 2.37% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

+19.0%

no trend

Dividend growing fast (19.0% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial